VCM
ORKA

Voleon Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Voleon Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.99M Buy
40,539
+16,991
+72% +$590K 0.04% 331
2025
Q4 		$714K Buy
+23,548
New +$656K 0.02% 505

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Voleon Capital Management's ORKA Position: Q1 2026 in Review

Voleon Capital Management increased its Oruka Therapeutics (ORKA) stake by 72% in Q1 2026, buying an estimated $590K and bringing the position to 40,539 shares worth $1.99M. The position accounts for 0.04% of the portfolio, ranked #331.

Voleon Capital Management first reported a position in ORKA in Q4 2025 and has held it in 2 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Voleon Capital Management held 40,539 shares of Oruka Therapeutics worth $1.99M as of Q1 2026.
  • Voleon Capital Management bought 16,991 Oruka Therapeutics shares in Q1 2026, an estimated $590K.
  • Oruka Therapeutics made up 0.04% of Voleon Capital Management's portfolio in Q1 2026, its #331 holding.
  • Voleon Capital Management first reported a position in Oruka Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.